JP2024510564A - ジヒドロエルゴタミン乾燥粉末製剤及びその使用方法 - Google Patents

ジヒドロエルゴタミン乾燥粉末製剤及びその使用方法 Download PDF

Info

Publication number
JP2024510564A
JP2024510564A JP2023553124A JP2023553124A JP2024510564A JP 2024510564 A JP2024510564 A JP 2024510564A JP 2023553124 A JP2023553124 A JP 2023553124A JP 2023553124 A JP2023553124 A JP 2023553124A JP 2024510564 A JP2024510564 A JP 2024510564A
Authority
JP
Japan
Prior art keywords
weight
dry powder
dhe
dry
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023553124A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024510564A5 (https=
Inventor
ペリー，ジェイスン，エム．
カラン，エイダン，ケイ．
ネルソン，アーロン，シー． ゴンザレス
ハンソン，デイナ，エフ．
ベルクソン，ヒラリー，ティー．
シュトルツ，エリック，シー．
Original Assignee
パルマトリックス オペレーティング カンパニー，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by パルマトリックス オペレーティング カンパニー，インコーポレイテッド filed Critical パルマトリックス オペレーティング カンパニー，インコーポレイテッド
Publication of JP2024510564A publication Critical patent/JP2024510564A/ja
Publication of JP2024510564A5 publication Critical patent/JP2024510564A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
JP2023553124A 2021-03-03 2022-03-01 ジヒドロエルゴタミン乾燥粉末製剤及びその使用方法 Pending JP2024510564A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163156111P 2021-03-03 2021-03-03
US63/156,111 2021-03-03
PCT/US2022/018306 WO2022187222A1 (en) 2021-03-03 2022-03-01 Dihydroergotamine dry power formulations and methods of use

Publications (2)

Publication Number Publication Date
JP2024510564A true JP2024510564A (ja) 2024-03-08
JP2024510564A5 JP2024510564A5 (https=) 2025-03-10

Family

ID=80781023

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023553124A Pending JP2024510564A (ja) 2021-03-03 2022-03-01 ジヒドロエルゴタミン乾燥粉末製剤及びその使用方法

Country Status (11)

Country Link
US (1) US20240033218A1 (https=)
EP (1) EP4301334A1 (https=)
JP (1) JP2024510564A (https=)
KR (1) KR20230152083A (https=)
CN (1) CN117222401A (https=)
AU (2) AU2022228443B2 (https=)
BR (1) BR112023017538A2 (https=)
CA (1) CA3210442A1 (https=)
IL (1) IL305506A (https=)
MX (1) MX2023010120A (https=)
WO (1) WO2022187222A1 (https=)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100081664A1 (en) * 2007-02-11 2010-04-01 Map Pharmaceuticals, Inc. Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
JP2012524716A (ja) * 2009-04-24 2012-10-18 イシューティカ ピーティーワイ リミテッド 高体積率で封入されるナノ粒子の作製
US20140179705A1 (en) * 2012-12-21 2014-06-26 Map Pharmaceuticals, Inc. 8'-hydroxy-dihydroergotamine compounds and compositions
JP2016515576A (ja) * 2013-04-01 2016-05-30 パルマトリックス，インコーポレイテッド チオトロピウム乾燥粉末
US20160263101A1 (en) * 2012-12-21 2016-09-15 Map Pharmaceuticals, Inc. 8'-hydroxy-dihydroergotamine compounds and compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
CN103200938B (zh) * 2010-08-30 2018-07-31 普马特里克斯营业公司 干燥粉末配方及用于治疗肺部疾病的方法
PT3470057T (pt) * 2010-09-29 2021-12-03 Pulmatrix Operating Co Inc Pós secos catiónicos compreendendo sais de magnésio
IL265913B2 (en) * 2016-10-14 2024-07-01 Pulmatrix Operating Co Inc Respirable Dry Powder Comprising Itraconazole In Crystalline Form And Its Use For Manufacturing A Medicament For Treating Fungal Infection

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100081664A1 (en) * 2007-02-11 2010-04-01 Map Pharmaceuticals, Inc. Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
JP2012524716A (ja) * 2009-04-24 2012-10-18 イシューティカ ピーティーワイ リミテッド 高体積率で封入されるナノ粒子の作製
US20140179705A1 (en) * 2012-12-21 2014-06-26 Map Pharmaceuticals, Inc. 8'-hydroxy-dihydroergotamine compounds and compositions
US20160263101A1 (en) * 2012-12-21 2016-09-15 Map Pharmaceuticals, Inc. 8'-hydroxy-dihydroergotamine compounds and compositions
JP2016515576A (ja) * 2013-04-01 2016-05-30 パルマトリックス，インコーポレイテッド チオトロピウム乾燥粉末

Also Published As

Publication number Publication date
IL305506A (en) 2023-10-01
EP4301334A1 (en) 2024-01-10
WO2022187222A1 (en) 2022-09-09
AU2025256073A1 (en) 2025-11-13
CA3210442A1 (en) 2022-09-09
US20240033218A1 (en) 2024-02-01
AU2022228443A1 (en) 2023-09-21
KR20230152083A (ko) 2023-11-02
MX2023010120A (es) 2023-10-30
AU2022228443B2 (en) 2025-07-24
WO2022187222A8 (en) 2023-11-02
CN117222401A (zh) 2023-12-12
BR112023017538A2 (pt) 2023-11-07

Similar Documents

Publication Publication Date Title
US20250221928A1 (en) Antifungal dry powders
JP7549534B2 (ja) イトラコナゾールを含む肺内投与のための抗真菌配合物
US20190167579A1 (en) Itraconazole dry powders
CN116687887A (zh) 用于吸入的干粉制剂
CA2963666A1 (en) Formulations containing tiotropium, amino acid and acid and methods thereof
JP2024510564A (ja) ジヒドロエルゴタミン乾燥粉末製剤及びその使用方法
US20250049717A1 (en) Dry powder formulations of narrow spectrum kinase inhibitors
WO2016057644A1 (en) Improved stability of dry powders containing tiotropium and amino acid
CN116744906A (zh) 用于制造包含伏立康唑的可吸入粉末的方法
HK40023697A (en) Ultra low density pulmonary powders
NZ793053A (en) Antifungal dry powders
BR112019007459B1 (pt) Pós secos antifúngicos e uso dos mesmos

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250228

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250228

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260217